产品说明
一般描述
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
生化/生理作用
酪氨酸蛋白激酶抑制剂; 在其他蛋白激酶反应中，ATP的竞争性抑制剂。 抗血管生成剂，可下调参与控制血管生成的基因的转录。
分析说明
These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
其他说明
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
附注
To see an example of a Certificate of Analysis for this material enter LRAB0086 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.
基本信息
| 经验(实验)分子式 | C15H10O5 |
| 分子量 | 270.24 |
| Beilstein | 263823 |
| EC 号 | 207-174-9 |
| MDL编号 | MFCD00016952 |
| NACRES | NA.24 |
产品性质
| 质量水平 | 300 |
| 等级 | certified reference material pharmaceutical secondary standard |
| CofA | current certificate can be downloaded |
| 包装 | pkg of 100 mL |
| application(s) | pharmaceutical |
| 格式 | neat |
| 药典可追溯性 | traceable to USP 1288816 |
| 储存温度 | -10 to -25℃ |
| SMILES string | Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O |
| InChI | 1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H |
| InChI key | TZBJGXHYKVUXJN-UHFFFAOYSA-N |
安全信息
| 象形图 |  |
| 警示用语： | Warning |
| 危险声明 | H302 |
| 预防措施声明 | P264 - P270 - P301 + P312 - P501 |
| 危险分类 | Acute Tox. 4 Oral |
| 储存分类代码 | 13 - Non Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
